There is no guaranteed way to prevent breast cancer from spreading, but a combination of completing prescribed treatments, maintaining a healthy weight, and staying consistent with follow-up care can meaningfully lower the risk. For most people, the single biggest factor is finishing the full course of adjuvant therapy their oncologist recommends after surgery.
How Breast Cancer Spreads
Cancer cells spread through a process that starts when they loosen from the original tumor. Normally, breast cells are tightly bonded to their neighbors. During metastasis, some cells undergo a transformation that breaks those bonds and gives them the ability to migrate. These newly mobile cells can enter blood vessels or lymphatic channels, travel to distant organs, and re-establish tight bonds in a new location, forming a secondary tumor.
The most common sites for breast cancer metastasis are bone, lungs, liver, and brain. This process is not a single event but a chain of steps: detaching, surviving in the bloodstream, evading the immune system, and finding a hospitable environment in another organ. Treatments after surgery are designed to interrupt this chain at multiple points.
Adjuvant Therapy After Surgery
Adjuvant therapy, the treatment you receive after your primary tumor is removed, is the most evidence-backed tool for preventing metastasis. The specific regimen depends on your cancer’s biology, particularly whether it’s hormone receptor-positive, HER2-positive, or triple-negative.
For hormone receptor-positive breast cancer, which is the most common type, five years of hormone-blocking therapy reduces recurrence rates during the first decade by roughly 40% with tamoxifen and 50% with aromatase inhibitors. In postmenopausal women, extending aromatase inhibitor treatment beyond five years further reduces distant recurrence. These medications work by starving any remaining cancer cells of the hormones they need to grow, and completing the full prescribed course is critical. Stopping early, even by a few months, weakens that protection.
For triple-negative breast cancer, which lacks hormone receptors and the HER2 protein, options have expanded in recent years. Patients with BRCA gene mutations may be offered a targeted drug called olaparib after chemotherapy. In the OlympiA trial, olaparib significantly improved three-year rates of both distant disease-free survival and overall survival compared to placebo. Immune checkpoint inhibitors have also shown encouraging results in triple-negative disease, and chemotherapy before surgery (neoadjuvant chemotherapy) can help oncologists gauge how well the cancer responds, guiding further treatment decisions.
Body Weight and Chronic Inflammation
Carrying excess weight, particularly after menopause, is one of the most well-documented modifiable risk factors for breast cancer recurrence and progression. In postmenopausal women, the risk of hormone receptor-positive breast cancer rises roughly 33% for every five-point increase in BMI. Women with a BMI above 35 face nearly double the risk compared to those at a healthy weight.
The mechanism is inflammation. When fat cells grow too large, they become stressed, begin dying, and release inflammatory signals. Immune cells called macrophages swarm the dying fat cells and amplify the inflammation by releasing additional signaling molecules. This creates a low-grade, body-wide inflammatory state that promotes new blood vessel growth around tumors and can help cancer cells establish themselves in distant organs. In animal studies, this inflammatory cascade directly accelerated breast cancer progression.
Maintaining a BMI between 18.5 and 24.9 is the general target. If you’re currently above that range, even modest weight loss can reduce inflammatory markers. The goal isn’t perfection but a sustained shift toward a healthier body composition through changes you can maintain long term.
Diet and Exercise
The relationship between diet and recurrence is more nuanced than headlines suggest. The DIANA-5 randomized trial tested a Mediterranean-style diet emphasizing whole grains, legumes, vegetables, olive oil, and fish while limiting red meat, sugar, refined products, and dairy. When researchers compared the diet group to the control group, there was no significant difference in recurrence rates. However, when they looked at the women across both groups who actually changed their eating habits the most, those with the greatest dietary improvement reduced their recurrence risk by 41%. The benefit appeared strongest in premenopausal women with hormone receptor-positive cancers.
The takeaway: being assigned a diet plan didn’t help, but actually following one did. The pattern that showed benefit centered on whole, minimally processed plant foods, healthy fats, and fish, with limited sugar and red meat.
Exercise has a less clear-cut evidence base than many people assume. The LACE study of breast cancer survivors initially found that higher levels of moderate physical activity (six or more hours per week) were associated with reduced recurrence and mortality. But once researchers adjusted for tumor characteristics and other variables, the association weakened and lost statistical significance. That doesn’t mean exercise is useless. It helps with weight management, reduces inflammation, improves treatment tolerance, and has clear benefits for overall survival from all causes. It simply means the independent, direct effect on metastasis specifically is harder to isolate than popular media suggests. Aim for at least 150 minutes per week of moderate activity as a baseline for general health.
Bone-Targeted Prevention
Bone is the most common site of breast cancer metastasis, and there’s a specific intervention that can reduce that risk. Bisphosphonates, drugs originally developed for osteoporosis, have been shown to lower the rate of cancer returning in bone when given as part of adjuvant treatment. A large meta-analysis of over 18,700 patients across 26 trials found that bisphosphonates reduced 10-year bone recurrence from 9.0% to 7.8% overall.
The benefit was strongest in postmenopausal women. In that group, 6.6% of those taking a bisphosphonate experienced bone recurrence within ten years, compared to 8.8% of those who did not. Bisphosphonates also improved distant recurrence rates and breast cancer-specific survival in postmenopausal women. If you’re postmenopausal and have been diagnosed with early-stage breast cancer, ask your oncologist whether adding a bisphosphonate to your treatment plan makes sense.
Follow-Up Monitoring
After treatment, regular follow-up is essential, but what “regular” looks like may be simpler than you expect. Current guidelines from the American Cancer Society and the American Society of Clinical Oncology recommend a cancer-focused physical exam and health history review on a regular schedule, along with screening for new primary breast cancers (typically annual mammography). Routine blood work, CT scans, or bone scans are not recommended for patients without symptoms. The evidence consistently shows that intensive surveillance imaging in people who feel well does not improve outcomes.
That said, an emerging technology may eventually change this approach. Circulating tumor DNA (ctDNA) testing, sometimes called a liquid biopsy, can detect tiny fragments of cancer DNA in the blood before a recurrence becomes visible on imaging. In the EBLIS study, ctDNA was detected ahead of clinical recurrence in 30 of 34 patients who relapsed, with a median lead time of about 10.5 months and up to 38 months in some cases. Newer platforms have demonstrated sensitivity as high as 85 to 100% for detecting residual disease after treatment. These tests are not yet standard of care for routine monitoring, but they’re increasingly used in clinical trials and high-risk settings. If you’re at elevated risk for recurrence, it’s worth asking your care team whether ctDNA monitoring is available to you.
What Matters Most
The factors with the strongest evidence for preventing metastatic breast cancer, in order of impact, are completing your full course of adjuvant therapy, maintaining a healthy body weight, and keeping up with recommended follow-up visits. Diet quality matters when the changes are real and sustained, not token. Exercise supports the overall picture but works primarily through weight control and general health rather than a direct anti-metastasis effect. And for postmenopausal women, bisphosphonates offer a concrete, bone-specific layer of protection that’s often underutilized.